Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04632992
Title A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications

Advanced Solid Tumor

Therapies

Ipatasertib

Atezolizumab + Capecitabine

Entrectinib

Atezolizumab + Docetaxel

Ado-trastuzumab emtansine + Atezolizumab

Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf

Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf

Alectinib

GDC-0077

Pertuzumab/trastuzumab/hyaluronidase-zzxf

Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf

Atezolizumab + Paclitaxel

Ado-trastuzumab emtansine + Tucatinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST